Evidence map›Paper›PMID 25394580›Full record

ReviewNutrition research reviews2014

Biochemical markers for assessment of calcium economy and bone metabolism: application in clinical trials from pharmaceutical agents to nutritional products.

Jean-Philippe Bonjour, Wendy Kohrt, Régis Levasseur, Michelle Warren, Susan Whiting, Marius Kraenzlin

Open access · hybridAbstract readReview
In one paragraph

Review in Nutrition research reviews, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Bone biomarkers in post-polio clinic patients.Frontiers in endocrinology · 2025
    Article
  8. Anti-osteoporotic effects ofNutrition research and practice · 2024
    Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Observational
  17. Article
  18. Pharmacometrics and systems pharmacology for metabolic bone diseases.British journal of clinical pharmacology · 2019
    Review
  19. Update of the tolerable upper intake level for vitamin D for infants.EFSA journal. European Food Safety Authority · 2018
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Jean-Philippe BonjourDivision of Bone Disease, University Hospitals and Faculty of Medicine,Geneva,Switzerland.
Wendy KohrtDivision of Geriatric Medicine, University of Colorado,Denver,CO,USA.
Régis LevasseurService de Rhumatologie, CHU Angers,Angers,France.
Michelle WarrenDepartment of Obstetrics and Gynecology and Medicine,Columbia University Medical Center,New York,NY,USA.
Susan WhitingCollege of Pharmacy and Nutrition, University of Saskatchewan,Saskatoon,Canada.
Marius KraenzlinDivision of Endocrinology, Diabetes and Metabolism, University Hospital,Bale,Switzerland.
University of Colorado Denver · USUniversity of Saskatchewan · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nutrition plays an important role in osteoporosis prevention and treatment. Substantial progress in both laboratory analyses and clinical use of biochemical markers has modified the strategy of anti-osteoporotic drug development. The present review examines the use of biochemical markers in clinical research aimed at characterising the influence of foods or nutrients on bone metabolism. The two types of markers are: (i) specific hormonal factors related to bone; and (ii) bone turnover markers (BTM) that reflect bone cell metabolism. Of the former, vitamin D metabolites, parathyroid hormone, and insulin-like growth factor-I indicate responses to variations in the supply of bone-related nutrients, such as vitamin D, Ca, inorganic phosphate and protein. Thus modification in bone remodelling, the key process upon which both pharmaceutical agents and nutrients exert their anti-catabolic or anabolic actions, is revealed. Circulating BTM reflect either osteoclastic resorption or osteoblastic formation. Intervention with pharmacological agents showed that early changes in BTM predicted bone loss and subsequent osteoporotic fracture risk. New trials have documented the influence of nutrition on bone-tropic hormonal factors and BTM in adults, including situations of body-weight change, such as anorexia nervosa, and weight loss by obese subjects. In osteoporosis-prevention studies involving dietary manipulation, randomised cross-over trials are best suited to evaluate influences on bone metabolism, and insight into effects on bone metabolism may be gained within a relatively short time when biochemical markers are monitored.

Indexed as

DietOsteoporosisBiomarkersBone and BonesBone Density Conservation AgentsCalciumClinical Trials as TopicHumansNutritional StatusBiomarkersBone Density Conservation AgentsCalciumBone-related hormonesBone turnover markersClinical nutrition trials

Identifiers

PMID25394580
PMCPMC4307651
OpenAlexW2107055546

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.